Efdamrofusp alfa
Based on 1 publication(s) in Google Scholar
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.89%
- No. CAS: 2375661-82-6
- Peso molecular:140.4 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Efdamrofusp alfa
MoreVer todos los productos específicos de isoformas VEGFR
More
Actividad biológica
Efdamrofusp alfa (0.135 mg/mL; 0, 6, 12, or 24 h) suppresses endothelial cell migration and tube formation[1].
Efdamrofusp alfa (0-1000 μg/mL) inhibits complement activation in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human primary umbilical vein endothelial cell (HUVEC)
-
Concentration:0.135 mg/mL
-
Incubation Time:0, 6, 12, or 24 h
-
Result:Showed a 20.91% reduction in migration.
Efdamrofusp alfa (1.35 mg; single intravitreal injection) shows favorable safety profiles and exhibited antiangiogenetic efficacy in a nonhuman primate laser-induced CNV model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice[1]
-
Dosage:13.5 μg; 13.0 μg
-
Administration:3 days; 7days
-
Result:Significantly reduced C3d deposition.
Reduced vascular leakage at 7 days after laser-induced injury.
Significantly suppressed CNV formation 7 days after laser-induced injury.
Reduced the concentrations of vitreous VEGF-A.
-
Animal Model:Rhesus monkeys[1]
-
Dosage:1.35 mg
-
Administration:Single intravitreal injection
-
Result:Decreased the CNV leakage at 14 and 28 days and effectively reduced CNV volume 28 days.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor)domain 2 fragment (14-204)-KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309)domain 3 fragment (206-308)-IGHG1 Fc (Fragment constant (205-431))-CR1 (complement receptor type 1, C3b/C4b receptor, C3BR, Knops blood group, KN, CD35)fragment (1-192)
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 2375661-82-6
-
Appearance Liquid
-
Peso molecular 140.4 kDa
-
Color Colorless to light yellow
-
SMILES
[Efdamrofusp alfa]
-
Synonyms
IBI302
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureza y Documentación
-
Ficha de datos (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)